StockNews.AI
VNRX
StockNews.AI
144 days

Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025

1. VolitionRx presents two studies at the European Lung Cancer Congress 2025. 2. Nu.Q® H3K27Me3 biomarker shows promise for NSCLC prognosis improvement. 3. Nu.Q® H3.1 assay aims for early cancer risk identification. 4. Studies include patient data for improved survival insights. 5. Presentations may enhance Volition's visibility in cancer diagnostics.

9m saved
Insight
Article

FAQ

Why Bullish?

Volition's advancements in cancer diagnostics may attract investor interest, reflecting historical trends where FDA approvals or significant research findings resulted in stock price increases.

How important is it?

The studies presented can significantly influence clinical practices in NSCLC, positioning Volition favorably in the market.

Why Long Term?

Continued research and future validation can establish market position, thus enhancing long-term growth prospects similar to past biotech advancements leading to widespread acceptance.

Related Companies

MDGLFGENGRTS
Studies demonstrate how Volition's Nu.Q®H3K27Me3 biomarker, when combined with ctDNA, may improve the prognostic value for overall survival and could help inform treatment decisions in NSCLC; and how Volition's Nu.Q® H3.1, low-cost immunoassay may be utilized  for the early identification of subjects at high risk of cancer , /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two poster presentations at the European Society for Medical Oncology (ESMO)'s European Lung Cancer Congress 2025 (ELCC 2025). The studies demonstrate how Volition's Nu.Q® H3K27Me3 biomarker, when combined with circulating tumor DNA, may improve the prognostic value for overall survival and could help inform treatment decisions in Non Small Cell Lung Cancer (NSCLC); and how Volition's Nu.Q® H3.1, low-cost immunoassay may be utilized for the early identification of subjects at high risk of cancer. ELCC 2025 is taking place in Paris, France, from March 26-29, 2025. ELCC 2025 Poster Session DetailsPoster Session and Table: #282PTitle: "Early detection of stage I/II NSCLC by immunoassay of crosslinked plasma cell fee nucleosomes"Presenter: Jake Micallef, PhD, MBA, Volition Chief Scientific OfficerDate and Time: Friday, March 28, 2025, 1:00PM – 1:45PM (CET) Poster Session and Table: #395PTitle: "H3K27Me3-nucleosome is a strong prognostic biomarker in non-small cell lung cancer (NSCLC): Interim results from the analysis of up to 832 patients at baseline"Presenter: Marie Piecyk, PhD, Researcher, Center for Innovation in Cancerology of Lyon (CICLY), Hospices Civils de Lyon, Faculty of Medicine and Maieutic Lyon Sud, Claude Bernard University LyonDate and Time: Friday, March 28, 2025, 1:00PM – 1:45PM (CET) The poster presentations can be viewed at#282P#395P About VolitionVolition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life. Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.  The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document.  Such website address is included in this document as an inactive textual reference only. Media Enquiries:Louise Batchelor, Volition, [email protected] +44 (0)7557 774620 Investor Relations:Jeremy Feffer, LifeSci Advisors, [email protected] +1-212-915-2568 Safe Harbor StatementStatements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, , the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this press release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances. Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. SOURCE VolitionRx Limited WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News